Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix.

Preparation and characterization of a controlled release system of rhodium (II) citrate, acetate. propionate, butyrate and their inclusion or association compounds with cyclodextrin (CD) are described. The porous hydroxyapatite (HA) was characterized by X-ray powder pattern diffraction, FTIR and solid state 31P NMR. Scanning electron microscopy and gas adsorption analysis (BET) were also performed. Release profiles of rhodium (II) carboxylates and their inclusion or association compounds from HA matrix were obtained at different drug loadings (5% and 10%). These were reasonably consistent with a diffusion model. This analysis, mainly using rhodium (II) citrate and butyrate, showed that the strategy of using CDs with a HA matrix may offer a useful new method for the controlled release of these compounds, and hence an alternative strategy for the controlled release of chemotherapeutic agents containing toxic metals. This may be a valuable new technique for localized anti-tumour chemotherapy that minimizes the side effects of such agents.

[1]  W. Wendlandt,et al.  The thermal decomposition of the dimethyl sulfoxide and pyridine adducts of rhodium(II) acetate, propionate and butyrate , 1976 .

[2]  O. L. Alves,et al.  The inclusion of rhodium(II)α-methyl-cinnamate in β-cyclodextrin , 1995 .

[3]  D. Wise,et al.  Medical Applications of Controlled Release , 2019 .

[4]  J. M. Marchetti,et al.  Potential use of gelcasting hydroxyapatite porous ceramic as an implantable drug delivery system. , 2001, International journal of pharmaceutics.

[5]  N A Peppas,et al.  New challenges in biomaterials. , 1994, Science.

[6]  J. Calhoun,et al.  Treatment of Osteomyelitis With a Biodegradable Antibiotic Implant , 1997, Clinical orthopaedics and related research.

[7]  H. Benson,et al.  Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody responses in sheep. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[8]  J. Fox,et al.  A novel skeletal drug delivery system using self-setting calcium phosphate cement VIII: the relationship between in vitro and in vivo drug release from indomethacin-containing cement , 1997 .

[9]  F. Hirayama,et al.  Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.

[10]  B Dhillon,et al.  Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS , 1998, International journal of STD & AIDS.

[11]  T. Yotsuyanagi,et al.  Synthesis of antibiotic-loaded hydroxyapatite beads and in vitro drug release testing. , 1992, Journal of biomedical materials research.

[12]  J. Waugh,et al.  High-resolution variable-temperature phosphorus-31 NMR of solid calcium phosphates , 1980 .

[13]  J. Fox,et al.  Effect of geometrical cement size on in vitro and in vivo indomethacin release from self-setting apatite cement. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[14]  F. Hirayama,et al.  Release characteristics of a short-chain fatty acid, n-butyric acid, from its beta-cyclodextrin ester conjugate in rat biological media. , 2000, Journal of pharmaceutical sciences.

[15]  Larry L. Hench,et al.  Bioceramics: Materials and Applications II , 1996 .

[16]  Robert Langer,et al.  Drugs on Target , 2001, Science.

[17]  Robert Langer,et al.  Zero-order release of micro- and macromolecules from polymeric devices: the role of the burst effect , 1997 .

[18]  P. Anderson,et al.  Preparation and characterisation of monoclinic hydroxyapatite and its precipitated carbonate apatite intermediate. , 2000, Biomaterials.

[19]  E. Sherwood,et al.  Hydrophobicity of several rhodium(II) carboxylates correlated with their biologic activity. , 1977, Journal of medicinal chemistry.

[20]  R. Langer,et al.  Encapsulation and release of rhodium(II) citrate and its association complex with hydroxypropyl-beta-cyclodextrin from biodegradable polymer microspheres. , 1999, Journal of pharmaceutical sciences.

[21]  M. L. Smith,et al.  Rhodium (II) butyrate: a potential anticancer drug with cell cycle phase-specific effects in HeLa cells. , 1980, Journal of the National Cancer Institute.

[22]  Y. Katagiri,et al.  Development of porous apatite ceramic for local delivery of chemotherapeutic agents. , 1998, Journal of biomedical materials research.

[23]  A. S. Posner,et al.  Crystal Structure of Hydroxyapatite , 1964, Nature.

[24]  J. Bear,et al.  Studies of Rhodium(II) Carboxylates as Potential Antitumor Agents 1 , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[25]  S. D. Robinson,et al.  Rhodium(II) carboxylates , 1983 .

[26]  J. Szejtli.  Utilization of cyclodextrins in industrial products andprocesses , 1997 .

[27]  A. Jillavenkatesa,et al.  Sol–gel processing of hydroxyapatite , 1998 .

[28]  H. Eckert,et al.  Hydrogen environments in calcium phosphates: proton MAS NMR at high spinning speeds , 1987 .

[29]  Jean-Marie Lehn,et al.  Comprehensive Supramolecular Chemistry , 1996 .

[30]  S. Lehnert,et al.  Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation. , 1997, International journal of radiation oncology, biology, physics.

[31]  A. Ślósarczyk,et al.  The kinetics of pentoxifylline release from drug-loaded hydroxyapatite implants. , 2000, Biomaterials.